Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for advanced kidney cancer: belzutifan takes on everolimus in major trial

NCT ID NCT04195750

Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial compares the experimental drug belzutifan to the standard drug everolimus in 755 people with advanced kidney cancer that has worsened after prior treatments. The goal is to see if belzutifan can better delay cancer growth and improve survival. Participants take oral tablets daily, and the study is currently active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Belzutifan (also known as MK-6482, WELIREG) and everolimus (also known as Afinitor, Zortress)
What this could lead to
If belzutifan works better than everolimus, it could become a new standard treatment for advanced kidney cancer, helping patients live longer without their disease getting worse.
What could go wrong
This is a late-stage trial, but belzutifan may not prove superior to everolimus. Side effects are possible with both drugs, and results may not apply to all kidney cancer patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

755 people

The number who actually took part.

Started

Feb 2020

Expected to finish

Sep 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Has unresectable, locally advanced or metastatic clear cell renal cell carcinoma (RCC) * Has had disease progression on or after having received systemic treatment for locally advanced or metastatic RCC with both Programmed cell death 1 ligand 1 (PD-1/L1) checkpoint inhibitor and a vascular endothelial growth factor - tyrosine kinase inhibitor (VEGF-TKI) in sequence or in combination * Has received no more than 3 prior systemic regimens for locally advanced or metastatic RCC * A male participant is eligible to participate if he is abstinent from heterosexual intercourse or agrees to use contraception during the intervention period and for at least 7 days after the last dose of study intervention * A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least 1 of the following conditions applies: Not a woman of childbearing potential (WOCBP) OR a WOCBP who agrees to follow the contraceptive guidance during the intervention period and for at least 30 days after the last dose of study intervention for those randomized to belzutifan and for at least 8 weeks after the last dose of study intervention for those randomized to everolimus * The participant (or legally acceptable representative if applicable) has provided documented informed consent for the study * Has adequate organ function Exclusion Criteria: * Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. (Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ \[e.g., breast carcinoma, cervical cancer in situ\] that have undergone potentially curative therapy are not excluded) * Has known central nervous system (CNS) metastases and/or carcinomatous meningitis. (Participants with previously treated brain metastases may participate provided they are radiologically stable for at least 4 weeks (28 days) by repeat imaging) * Has clinically significant cardiac disease, including unstable angina, acute myocardial infarction within 6 months from Day 1 of study medication administration, or New York Heart Association Class III or IV congestive heart failure. (Medically controlled arrhythmia stable on medication is permitted) * Has poorly controlled hypertension defined as systolic blood pressure (SBP) ≥150 mm Hg and/or diastolic blood pressure (DBP) ≥90 mm Hg * Has moderate to severe hepatic impairment (Child-Pugh B or C) * Has a known psychiatric or substance abuse disorder that would interfere with cooperation with the requirements of the study * Is unable to swallow orally administered medication or has a gastrointestinal disorder affecting absorption (e.g., gastrectomy, partial bowel obstruction, malabsorption) * Has known hypersensitivity or allergy to the active pharmaceutical ingredient or any component of the study intervention (belzutifan or everolimus) formulations * Has received prior treatment with belzutifan or another hypoxia inducible factor 2α (HIF-2α inhibitor) * Has received prior treatment with everolimus or any other specific or selective target of rapamycin complex 1 (TORC1)/ phosphatidylinositol 3-kinase (PI3K)/ protein kinase B (AKT) inhibitor (e.g., temsirolimus) in the advanced disease setting * Has received any type of systemic anticancer antibody (including investigational antibody) within 4 weeks before randomization * Has received prior radiotherapy within 2 weeks prior to randomization * Has had major surgery within 3 weeks prior to randomization * Has received a live vaccine within 30 days prior to randomization. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines are live attenuated vaccines and are not allowed * Is currently receiving either strong (e.g., itraconazole, telithromycin, clarithromycin, protease inhibitors boosted with ritonavir or cobicistat, indinavir, saquinavir, nelfinavir, boceprevir, telaprevir) or moderate (e.g., ciprofloxacin, erythromycin, diltiazem, fluconazole, verapamil) inhibitors of cytochrome P450 3A4 (CYP3A4) that cannot be discontinued for the duration of the study * Is currently receiving either strong (phenobarbital, enzalutamide, phenytoin, rifampicin, rifabutin, rifapentine, carbamazepine, nevirapine and St John's Wort) or moderate (e.g., bosentan, efavirenz, modafinil) inducers of CYP3A4 that cannot be discontinued for the duration of the study * Is currently participating in a study of an investigational agent or is currently using an investigational device * Has an active infection requiring systemic therapy * Has active bacillus tuberculosis (TB) * Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to randomization * Has a known history of human immunodeficiency virus (HIV) infection. (Testing for HIV at screening is only required if mandated by local health authority * Has a known history of Hepatitis B virus (HBV) (defined as Hepatitis B surface antigen \[HBsAg\] reactive) or known active Hepatitis C virus (HCV) (defined as HCV ribonucleic acid \[RNA\] \[qualitative\] is detected) infection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carcinoma, renal cell are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

kidney cancer nonpapillary renal cell carcinoma renal cell adenocarcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carcinoma, renal cell

Contacts and locations

Locations

  • AOU di Bologna Policlinico S Orsola Malpighi ( Site 0606)

    Bologna, 40138, Italy

  • Aarhus University Hospital Skejby ( Site 0250)

    Aarhus, Central Jutland, 8200, Denmark

  • Abramson Cancer Center ( Site 1525)

    Philadelphia, Pennsylvania, 19104, United States

  • Administradora Country SA - Clinica del Country ( Site 1701)

    Bogotá, Bogota D.C., 110221, Colombia

  • Akershus universitetssykehus ( Site 0851)

    Lorenskog, Akershus, 1478, Norway

  • Ankara Universitesi Tip Fakultesi ( Site 1311)

    Ankara, 06100, Turkey (Türkiye)

  • Asan Medical Center ( Site 1200)

    Seoul, 05505, South Korea

  • Azienda Ospedaliera Policlinico di Bari ( Site 0610)

    Bari, 70124, Italy

  • Azienda Ospedaliera Santa Maria ( Site 0602)

    Terni, 05100, Italy

  • Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento-Oncology Unit ( Site 0605)

    Verona, Veneto, 37126, Italy

  • Azienda Ospedaliero Universitaria di Modena Policlinico ( Site 0604)

    Modena, 41125, Italy

  • BC Cancer - Vancouver Center ( Site 0155)

    Vancouver, British Columbia, V5Z 4E6, Canada

  • BP - A Beneficencia Portuguesa de São Paulo ( Site 1653)

    São Paulo, São Paulo, 01323-001, Brazil

  • Barts Health NHS Trust ( Site 1407)

    London, London, City of, EC1A 7BE, United Kingdom

  • Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 0505)

    Gyula, Bekes County, H-5700, Hungary

  • Beth Israel Deaconess Medical Center ( Site 1501)

    Boston, Massachusetts, 02215, United States

  • Borsod-Abaúj-Zemplén Megyei Központi Kórház és Egyetemi Okta-Klinikai Onkológiai és Sugárterápiás Ce ( Site 0502)

    Miskolc, Borsod-Abauj Zemplen county, 3526, Hungary

  • Bradfordhill ( Site 0003)

    Santiago, Region M. de Santiago, 8420383, Chile

  • CHU Besancon - Hopital Jean Minjoz ( Site 0351)

    Besançon, Doubs, 25000, France

  • CHU de Bordeaux Hop St ANDRE ( Site 0359)

    Bordeaux, Aquitaine, 33075, France

  • Cambridge University Hospitals NHSFT ( Site 1405)

    Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom

  • Cancer Institute Hospital of JFCR ( Site 1000)

    Tokyo, 135-8550, Japan

  • Central Clinical Hospital with Polyclinic ( Site 1157)

    Moscow, Moscow, 121359, Russia

  • Centre Francois Baclesse ( Site 0360)

    Caen, Calvados, 14075, France

  • Centre Hospitalier Lyon Sud ( Site 0354)

    Pierre-Bénite, Rhone, 69310, France

  • Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0151)

    Montreal, Quebec, H2X 3E4, Canada

  • Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0152)

    Québec, Quebec, G1J 1Z4, Canada

  • Centro Avançado de Tratamento Oncológico- CENANTRON ( Site 1657)

    Belo Horizonte, Minas Gerais, 30130-090, Brazil

  • Centro Investigación del Cáncer James Lind ( Site 0004)

    Temuco, Araucania, 4800827, Chile

  • Chang Gung Medical Foundation - Kaohsiung ( Site 1104)

    Kaohsiung City, 83301, Taiwan

  • Chang Gung Medical Foundation-Linkou Branch-Urology ( Site 1106)

    Taoyuan, 333, Taiwan

  • Chungnam National University Hospital ( Site 1205)

    Daejeon, Taejon-Kwangyokshi, 35015, South Korea

  • City clinical oncological dispensary ( Site 1154)

    Saint Petersburg, Sankt-Peterburg, 198255, Russia

  • Cleveland Clinic Main ( Site 1504)

    Cleveland, Ohio, 44195, United States

  • Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 1702)

    Bogotá, Bogota D.C., 111321, Colombia

  • Dana Farber Cancer Institute ( Site 1505)

    Boston, Massachusetts, 02215, United States

  • Debreceni Egyetem Klinikai Kozpont ( Site 0504)

    Debrecen, Hajdú-Bihar, 4032, Hungary

  • Ege Universitesi Tip Fakultesi Hastanesi ( Site 1304)

    Izmir, 35100, Turkey (Türkiye)

  • Ehime University Hospital ( Site 1014)

    Tōon, Ehime, 791-0295, Japan

  • Faculty Office Towers 1132 ( Site 1538)

    Birmingham, Alabama, 35294, United States

  • Fakultni Thomayerova nemocnice ( Site 0107)

    Prague, 140 59, Czechia

  • Fakultni nemocnice Hradec Kralove ( Site 0106)

    Hradec Králové, 50005, Czechia

  • Fakultni nemocnice Kralovske Vinohrady ( Site 0102)

    Prague, 100 34, Czechia

  • Fakultni nemocnice Olomouc ( Site 0104)

    Olomouc, 77900, Czechia

  • Fakultni nemocnice Ostrava ( Site 0103)

    Ostrava, Ostrava Mesto, 708 52, Czechia

  • First Moscow State Medical University n.a. I.M.Sechenov ( Site 1163)

    Moscow, Moscow, 119146, Russia

  • Fondazione Policlinico Universitario A. Gemelli ( Site 0607)

    Roma, 00168, Italy

  • Fondazione Salvatore Maugeri clinica del lavoro ( Site 0600)

    Pavia, 27100, Italy

  • Fox Chase Cancer Center ( Site 1506)

    Philadelphia, Pennsylvania, 19111, United States

  • Fujita Health University Hospital ( Site 1016)

    Toyoake, Aichi-ken, 470-1192, Japan

  • Fundacion Centro de Investigacion Clinica CIC ( Site 1703)

    Medellín, Antioquia, 050021, Colombia

  • Gazi Universitesi Tip Fakultesi ( Site 1308)

    Ankara, 06560, Turkey (Türkiye)

  • Gustave Roussy ( Site 0353)

    Villejuif, Val-de-Marne, 94800, France

  • Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 1303)

    Istanbul, 34722, Turkey (Türkiye)

  • HYKS. ( Site 0302)

    Helsinki, Uusimaa, 00290, Finland

  • Hacettepe Universitesi Tip Fakultesi ( Site 1300)

    Ankara, 06230, Turkey (Türkiye)

  • Hadassah Medical-Oncology department ( Site 1164)

    Moscow, Moscow Oblast, 121205, Russia

  • Hamamatsu University Hospital ( Site 1005)

    Hamamatsu, Shizuoka, 431-3192, Japan

  • Hattiesburg Clinic ( Site 1509)

    Hattiesburg, Mississippi, 39401, United States

  • Helse Bergen HF - Haukeland Universitetssykehus ( Site 0854)

    Bergen, Hordaland, 5021, Norway

  • Henry Ford Cancer Center ( Site 1511)

    Detroit, Michigan, 48202, United States

  • Henry Joyce Cancer Clinic ( Site 1544)

    Nashville, Tennessee, 37232, United States

  • Herlev Hospital ( Site 0251)

    Herlev, Capital Region, 2730, Denmark

  • Hiroshima University Hospital ( Site 1019)

    Hiroshima, 734-8551, Japan

  • Hospital General Universitario 12 de Octubre ( Site 1252)

    Madrid, 28041, Spain

  • Hospital Ramon y Cajal ( Site 1253)

    Madrid, 28034, Spain

  • Hospital Universitari Vall d Hebron ( Site 1250)

    Barcelona, Catalonia, 08035, Spain

  • Hospital de Clinicas de Porto Alegre ( Site 1655)

    Porto Alegre, Rio Grande do Sul, 90035-903, Brazil

  • Imperial Healthcare NHS Trust Charing Cross Hospital ( Site 1409)

    London, London, City of, W6 8RF, United Kingdom

  • Institut de Cancerologie du Gard - CHU Caremeau ( Site 0352)

    Nîmes, Gard, 30029, France

  • Institut de Cancérologie de Lorraine Alexis Vautrin ( Site 0356)

    Vandœuvre-lès-Nancy, Lorraine, 54519, France

  • Institut de cancérologie Strasbourg Europe (ICANS) ( Site 0350)

    Strasbourg, Alsace, 67200, France

  • Instituto Catalan de Oncologia - ICO ( Site 1251)

    Barcelona, Catalonia, 08908, Spain

  • Instituto Valenciano de Oncologia - IVO ( Site 1254)

    Valencia, Valenciana, Comunitat, 46009, Spain

  • Instituto de Cancer e Transplante de Curitiba ICTR ( Site 1650)

    Curitiba, Paraná, 80510-130, Brazil

  • Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 1305)

    Istanbul, 34098, Turkey (Türkiye)

  • Istituto Nazionale dei Tumori ( Site 0601)

    Milan, 20133, Italy

  • Istituto Oncologico Veneto IRCCS ( Site 0603)

    Padova, 35128, Italy

  • Izmir Katip Celebi Universitesi Ataturk Egitim ve Arastirma Hastanesi ( Site 1306)

    Izmir, 35360, Turkey (Türkiye)

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 1513)

    Hackensack, New Jersey, 07601, United States

  • Juravinski Cancer Centre ( Site 0154)

    Hamilton, Ontario, L8V 5C2, Canada

  • Kanagawa Cancer Center ( Site 1021)

    Yokohama, Kanagawa, 241-8515, Japan

  • Karolinska Universitetssjukhuset Solna ( Site 1850)

    Stockholm, Stockholm County, 171 76, Sweden

  • Keio University Hospital ( Site 1002)

    Tokyo, 160-8582, Japan

  • Kindai University Hospital ( Site 1011)

    Sayama, Osaka, 589-8511, Japan

  • Korea University Anam Hospital ( Site 1203)

    Seoul, 02841, South Korea

  • Krasnoyarsk Regional Clinical Oncological Dispensary ( Site 1151)

    Krasnoyarsk, Krasnoyarsk Krai, 660133, Russia

  • Kuopion Yliopistollinen Sairaala ( Site 0304)

    Kuopio, Northern Savonia, 70210, Finland

  • Kyiv City Clinical Oncology Center ( Site 1450)

    Kyiv, 03115, Ukraine

  • Kyushu University Hospital ( Site 1007)

    Fukuoka, 812-8582, Japan

  • Laenssjukhuset Ryhov ( Site 1853)

    Jönköping, Jönköping County, 551 85, Sweden

  • Liga Norte Riograndense Contra o Cancer ( Site 1651)

    Natal, Rio Grande do Norte, 59062-000, Brazil

  • ME І.І. Mechnykov Dnipro Regional Clinical Hospital ( Site 1453)

    Dnipropetrovsk, Dnipropetrovsk Oblast, 49005, Ukraine

  • MI Precarpathian Clinical Oncology Center ( Site 1452)

    Ivano-Frankivsk, Ivano-Frankivsk Oblast, 76018, Ukraine

  • Malmo Universitetssjukhus ( Site 1851)

    Malmö, Skåne County, 214 28, Sweden

  • Masarykuv onkologicky ustav ( Site 0105)

    Brno, Brno-mesto, 656 53, Czechia

  • Massachusetts General Hospital ( Site 1558)

    Boston, Massachusetts, 02114, United States

  • Medical Oncology Ospedale San Donato ( Site 0609)

    Arezzo, 52100, Italy

  • Medical University of South Carolina ( Site 1518)

    Charleston, South Carolina, 29425, United States

  • Medway Maritime Hospital ( Site 1406)

    Gillingham, ME7 5NY, United Kingdom

  • N.N. Blokhin NMRCO ( Site 1156)

    Moscow, Moscow, 115478, Russia

  • Nara Medical University Hospital ( Site 1009)

    Kashihara, Nara, 634-0813, Japan

  • National Cancer Center ( Site 1204)

    Gyeonggi-do, Kyonggi-do, 10408, South Korea

  • National Cancer Center Hospital ( Site 1003)

    Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East ( Site 1001)

    Kashiwa, Chiba, 2778577, Japan

  • National Cheng Kung University Hospital ( Site 1103)

    Tainan, 704, Taiwan

  • National Taiwan University Hospital ( Site 1100)

    Taipei, 10002, Taiwan

  • Niigata University Medical & Dental Hospital ( Site 1022)

    Niigata, 951-8520, Japan

  • Nippon Medical School Hospital ( Site 1010)

    Bunkyo-ku, Tokyo, 113-8603, Japan

  • Norrlands Universitetssjukhus ( Site 1856)

    Umeå, Västerbotten County, 901 85, Sweden

  • Northwest Georgia Oncology Centers PC ( Site 1520)

    Marietta, Georgia, 30060, United States

  • Nova Scotia Health Authority QEII-HSC ( Site 0150)

    Halifax, Nova Scotia, B3H 1V7, Canada

  • Ochsner Medical Center ( Site 1522)

    New Orleans, Louisiana, 70121-2429, United States

  • Okayama University Hospital ( Site 1020)

    Okayama, 700-8558, Japan

  • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 1523)

    Tulsa, Oklahoma, 74146, United States

  • Omsk Clinical Oncology Dispensary ( Site 1150)

    Omsk, Omsk Oblast, 644013, Russia

  • Oncologos del Occidente S.A. ( Site 1708)

    Pereira, Risaralda Department, 660006, Colombia

  • Oncology Hematology Care, Inc. ( Site 1524)

    Cincinnati, Ohio, 45242, United States

  • Oregon Health & Science University ( Site 1553)

    Portland, Oregon, 97239, United States

  • Orszagos Onkologiai Intezet ( Site 0503)

    Budapest, 1122, Hungary

  • Prince of Wales Hospital ( Site 1050)

    Hong Kong, Hong Kong

  • Princess Margaret Hospital. ( Site 1053)

    Lai Chi Kok, Hong Kong

  • Queen Elizabeth Hospital. ( Site 1052)

    Kowloon, Hong Kong

  • Queen Mary Hospital ( Site 1051)

    Hong Kong, 000000, Hong Kong

  • Royal Marsden Hospital Sutton-Surrey ( Site 1411)

    Sutton, London, City of, SM2 5PT, United Kingdom

  • Royal Marsden NHS Foundation Trust ( Site 1403)

    London, London, City of, SW3 6JJ, United Kingdom

  • Russian Scientific Center of Radiology and Surgical Technologies ( Site 1153)

    Saint Petersburg, Sankt-Peterburg, 197758, Russia

  • Russian Scientific Center of Roentgenoradiology ( Site 1155)

    Moscow, Moscow, 117997, Russia

  • SBHI SPb Clinical Research Centre of specialized types of medical care ( Site 1159)

    Saint Petersburg, Sankt-Peterburg, 197758, Russia

  • SBIH City clinical hospital named after D.D. Pletniov ( Site 1160)

    Moscow, Moscow, 105077, Russia

  • Saitama Medical University International Medical Center ( Site 1012)

    Hidaka, Saitama, 350-1298, Japan

  • Samsung Medical Center ( Site 1201)

    Seoul, 06351, South Korea

  • Sapporo Medical University Hospital ( Site 1008)

    Sapporo, Hokkaido, 060-8543, Japan

  • Semmelweis Egyetem ( Site 0501)

    Budapest, 1085, Hungary

  • Severance Hospital Yonsei University Health System ( Site 1202)

    Seoul, 03722, South Korea

  • Sibley Memorial Hospital ( Site 1559)

    Washington D.C., District of Columbia, 20016, United States

  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ( Site 1514)

    Baltimore, Maryland, 21287, United States

  • Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 1709)

    Valledupar, Cesar Department, 200001, Colombia

  • St. Joseph Heritage Healthcare Local Lab ( Site 1531)

    Santa Rosa, California, 95403, United States

  • St. Vincent Frontier Cancer Center ( Site 1549)

    Billings, Montana, 59102, United States

  • Sunnybrook Research Institute ( Site 0153)

    Toronto, Ontario, M4N 3M5, Canada

  • TYKS T-sairaala Syopatautien pkl ( Site 0301)

    Turku, Southwest Finland, 20520, Finland

  • Taichung Veterans General Hospital ( Site 1105)

    Taichung, 407, Taiwan

  • Taipei Veterans General Hospital ( Site 1101)

    Taipei, 11217, Taiwan

  • Tampereen yliopistollinen sairaala ( Site 0300)

    Tampere, Pirkanmaa, 33520, Finland

  • Texas Oncology, P.A.-Dallas ( Site 1534)

    Dallas, Texas, 75230, United States

  • Texas Oncology-Austin Central ( Site 1533)

    Austin, Texas, 78731, United States

  • The Beatson West of Scotland Cancer Centre ( Site 1402)

    Glasgow, Glasgow City, G12 0YN, United Kingdom

  • The Christie NHS Foundation Trust ( Site 1401)

    Manchester, M20 4BX, United Kingdom

  • The University of Chicago Medical Center ( Site 1539)

    Chicago, Illinois, 60637, United States

  • The University of Osaka Hospital ( Site 1006)

    Suita, Osaka, 565-0871, Japan

  • Tokushima University Hospital ( Site 1017)

    Tokushima, 770-8503, Japan

  • Toranomon Hospital ( Site 1004)

    Tokyo, 105-8470, Japan

  • Toyama University Hospital ( Site 1013)

    Toyoma, Toyama, 930-0194, Japan

  • Trakya University Medical Faculty Balkan Oncology Hospital ( Site 1302)

    Edirne, 22030, Turkey (Türkiye)

  • UCHealth Highlands Ranch Hospital ( Site 1560)

    Highlands Ranch, Colorado, 80129, United States

  • Universitaetsklinik fuer Urologie ( Site 0405)

    Tübingen, Baden-Wurttemberg, 72076, Germany

  • Universitaetsklinikum Carl Gustav Carus Dresden ( Site 0403)

    Dresden, Saxony, 01307, Germany

  • Universitaetsklinikum Duesseldorf ( Site 0410)

    Düsseldorf, North Rhine-Westphalia, 40225, Germany

  • Universitaetsklinikum Essen ( Site 0401)

    Essen, North Rhine-Westphalia, 45122, Germany

  • Universitaetsklinikum Jena ( Site 0402)

    Jena, Thuringia, 07747, Germany

  • Universitaetsklinikum Magdeburg A.o.R. ( Site 0404)

    Magdeburg, Saxony-Anhalt, 39120, Germany

  • Universitaetsmedizin Berlin ( Site 0400)

    Berlin, 10117, Germany

  • Universitatsklinikum Hamburg ( Site 0408)

    Hamburg, 20246, Germany

  • University of California San Diego Moores Cancer Center ( Site 1546)

    La Jolla, California, 92093-0698, United States

  • University of Colorado Cancer Center ( Site 1540)

    Aurora, Colorado, 80045, United States

  • University of North Carolina at Chapel Hill ( Site 1537)

    Chapel Hill, North Carolina, 27514, United States

  • University of Rochester Medical Center ( Site 1543)

    Rochester, New York, 14642, United States

  • Western General Hospital ( Site 1400)

    Edinburgh, Edinburgh, City of, EH4 2XU, United Kingdom

  • Yamaguchi University Hospital ( Site 1018)

    Ube, Yamaguchi, 755-8505, Japan

  • Yokohama City University Hospital ( Site 1015)

    Yokohama, Kanagawa, 236-0004, Japan

  • Zala Megyei Szent Rafael Korhaz ( Site 0509)

    Zalaegerszeg, 8900, Hungary

More trials for these conditions

Other studies related to the condition(s) this trial covers.